Soleno Therapeutics
SLNO
Performance
About Soleno Therapeutics
Soleno Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Headquartered in Redwood City, California, the company aims to bring therapies for life-threatening genetic disorders to patients and families worldwide. Its efforts emphasize translating promising research into clinically meaningful treatments for underserved rare-disease populations.
Recent News
Neurocrine to Acquire Soleno for $2.9 B, Paying $53 per Share in Cash
Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal
Under FDA Clinical Hold, Aardvark Therapeutics Seeks Path Forward for Metabolic Drug
ASX Set to Retreat, Wall Street Loses Steam After Trump’s Threat to ‘Take Out’ Iran; Oil Rises
STAT+: Stealth Biotech Stipple Bets on Secretive ADCs
Neurocrine to Acquire Soleno Therapeutics for $2.9 Billion in Cash
Top Biotech Deals in April 2026
Trump’s New Pharmaceutical Tariffs Will Hit Small Drugmakers Hardest
Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion in Cash